Sebastiao et al. (2018) have suggested that A2AR stimulation or inhibition could play a different role at early and late stages of ALS, since accumulating lines of evidence indicate a beneficial role of both agonists and antagonists of A2AR. The gene discussed is ADORA2A; the disease is amyotrophic lateral sclerosis.